AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10357168 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 7532382 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge instructions with illustrations (n = 54)
Number of subjects: 101
Study 7532382 — intervention group
Group type: COMPARATOR
Intervention: Discharge instructions without illustrations (n = 47)
Number of subjects: 101
Study 7532382 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge instructions with illustrations among nonwhites (n = 51)
Number of subjects: 101
Study 7532382 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge instructions with illustrations among patients with no more than a high school education (n = 71)
Number of subjects: 101
Study 7532382 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge instructions with illustrations among women (n = 48)
Number of subjects: 101
Study 1789096 — intervention group
Group type: EXPERIMENTAL
Intervention: Astigmatism treatment
Number of subjects: 238
Study 7340895 — intervention group
Group type: EXPERIMENTAL
Intervention: Signaled running time task with a preparatory interval of 10, 15, or 20 sec.
Number of subjects: 16
Study 30721572 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 3 mg daily for 26 weeks
Number of subjects: 30
Study 30721572 — intervention group
Group type: COMPARATOR
Intervention: Diet and exercise (energy restriction plus moderate-intensity exercise) for 26 weeks
Number of subjects: 30
Study 27838115 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (2.5-4 percent) inhalation in Group S (n=7)
Number of subjects: 14
Study 27838115 — intervention group
Group type: COMPARATOR
Intervention: Propofol infusion (1-2mg·kg-1·min-1) in Group P (n=7)
Number of subjects: 14
Study 26886026 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing for herpes simplex virus type 2 (HSV-2)
Number of subjects: 32
Study 26886026 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed plan to disclose HSV-2 test results to adolescents only
Number of subjects: 32
Study 26886026 — intervention group
Group type: COMPARATOR
Intervention: Request for parental access to results
Number of subjects: 32
Study 25087907 — intervention group
Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope
Number of subjects: 128
Study 25087907 — intervention group
Group type: COMPARATOR
Intervention: McGrath(®) Series 5 videolaryngoscope
Number of subjects: 128
Study 22776970 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 5 mg daily
Number of subjects: 14
Study 22776970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 19734366 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) at -40 mmHg
Number of subjects: 12
Study 19734366 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) at -40 mmHg in ischemic cardiomyopathy (ICM) patients
Number of subjects: 12
Study 19734366 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor testing in ischemic cardiomyopathy (ICM) patients (n = 4)
Number of subjects: 12
Study 19734366 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) at -40 mmHg in nonischemic or dilated cardiomyopathy (DCM) patients
Number of subjects: 12
Study 19734366 — intervention group
Group type: COMPARATOR
Intervention: Lower body negative pressure (LBNP) at -40 mmHg in normal (N) group
Number of subjects: 12
Study 17466854 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (n = 20) received 20 mg/0.5 mL of methylprednisolone and 10 mg/0.5 mL of gentamicin injected into the posterior sub‐Tenon's space
Number of subjects: 40
Study 17466854 — intervention group
Group type: COMPARATOR
Intervention: Group B (n = 20) received the same combination injected into the anterior sub‐Tenon's space
Number of subjects: 40
Study 15754633 — intervention group
Group type: EXPERIMENTAL
Intervention: High voltage stimulation
Number of subjects: 25
Study 15754633 — intervention group
Group type: COMPARATOR
Intervention: Control (pharmacological treatment only)
Number of subjects: 25
Study 12105409 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2%
Number of subjects: 1893
Study 12105409 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 1%
Number of subjects: 1893
Study 12105409 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 1893
Study 10102969 — intervention group
Group type: EXPERIMENTAL
Intervention: olsalazine
Number of subjects: 15
Study 10102969 — intervention group
Group type: EXPERIMENTAL
Intervention: mesalazine
Number of subjects: 15
Study 10102969 — intervention group
Group type: COMPARATOR
Intervention: Comparison of olsalazine and mesalazine
Number of subjects: 15
Study 7586997 — intervention group
Group type: EXPERIMENTAL
Intervention: Med 15 (1.200 mg for 2 days, then 600 mg for 13 days)
Number of subjects: 30
Study 7586997 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam (same dosage regimen as Med 15)
Number of subjects: 30
Study 2251029 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk protein-enriched human milk
Number of subjects: 28
Study 2251029 — intervention group
Group type: COMPARATOR
Intervention: Protein-unenriched human milk
Number of subjects: 28
Study 6986027 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg every six hours)
Number of subjects: 75
Study 6986027 — intervention group
Group type: COMPARATOR
Intervention: Antacid (Mylanta II, 30 ml every hour)
Number of subjects: 75
Study 6986027 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine with antacid titration
Number of subjects: 75
Study 30673108 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoriasis incidence
Number of subjects: 14705
Study 30673108 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime prevalence of psoriasis
Number of subjects: 14705
Study 30673108 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality rate among psoriasis patients
Number of subjects: 14705
Study 27966574 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin (IN) 24g
Number of subjects: 25
Study 27966574 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant Starch (RS) 28.2g
Number of subjects: 25
Study 27966574 — intervention group
Group type: COMPARATOR
Intervention: Glucose (GLU) 75g
Number of subjects: 25
Study 25909567 — intervention group
Group type: COMPARATOR
Intervention: Any form of image guidance
Number of subjects: 50
Study 25909567 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented reality
Number of subjects: 50
Study 25909567 — intervention group
Group type: EXPERIMENTAL
Intervention: Always-on solid overlay
Number of subjects: 50
Study 25909567 — intervention group
Group type: EXPERIMENTAL
Intervention: Wire mesh and on-demand overlays
Number of subjects: 50
Study 25909567 — intervention group
Group type: EXPERIMENTAL
Intervention: Wire mesh and inverse realism overlays
Number of subjects: 50
Study 23964752 — intervention group
Group type: EXPERIMENTAL
Intervention: DDEA 1.16% gel (2 g, 4x/day, for 5 days)
Number of subjects: 72
Study 23964752 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 72
Study 21423115 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasoactive, antioxidant treatment and neuromidin (15 mg in solution for 10 days, then 20 mg three times a day for 2 months)
Number of subjects: 40
Study 21423115 — intervention group
Group type: COMPARATOR
Intervention: Vasoactive and antioxidant treatment
Number of subjects: 40
Study 19684171 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g of spread with a target dose of 1 x 10(9) CFU of L. reuteri DSM 17938
Number of subjects: 42
Study 19684171 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g of spread with a target dose of 5 x 10(9) CFU of L. rhamnosus GG
Number of subjects: 42
Study 19684171 — intervention group
Group type: COMPARATOR
Intervention: 20 g of placebo spread
Number of subjects: 42
Study 17766284 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 8 mg/day
Number of subjects: 118
Study 17766284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 14604267 — intervention group
Group type: EXPERIMENTAL
Intervention: Genistein (54 mg/day)
Number of subjects: 0
Study 14604267 — intervention group
Group type: COMPARATOR
Intervention: Hormone replacement therapy
Number of subjects: 0
Study 11020092 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 156
Study 11020092 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline therapy
Number of subjects: 156
Study 11020092 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of exercise and sertraline
Number of subjects: 156
Study 11020092 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise during follow-up
Number of subjects: 156
Study 9432270 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine pericardium patch angioplasty
Number of subjects: 52
Study 1469180 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (0.1‐0.6% in air‐oxygen mixture)
Number of subjects: 60
Study 1469180 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (continuous infusion of 0.02‐0.20 mg/kg/h)
Number of subjects: 60
Study 6325909 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated Oka/Merck varicella vaccine
Number of subjects: 956
Study 6325909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 956
Study 3787660 — intervention group
Group type: COMPARATOR
Intervention: 0.00 ppm SO2
Number of subjects: 27
Study 3787660 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 ppm SO2
Number of subjects: 27
Study 3787660 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50 ppm SO2
Number of subjects: 27
Study 3787660 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.00 ppm SO2
Number of subjects: 27
Study 3787660 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.00 ppm SO2
Number of subjects: 27
Study 29190319 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic radiotherapy (RT) with concurrent and adjuvant chemotherapy (two cycles of cisplatin 50 mg/m2 in weeks 1 and 4 of RT, followed by four cycles of carboplatin AUC5 and paclitaxel 175 mg/m2)
Number of subjects: 329
Study 29190319 — intervention group
Group type: COMPARATOR
Intervention: Pathology review
Number of subjects: 329
Study 27523919 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (0.1g/kg/day of creatine + 0.1g/kg/day of maltodextrin)
Number of subjects: 31
Study 27523919 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.2g/kg/day of maltodextrin)
Number of subjects: 31
Study 27523919 — intervention group
Group type: COMPARATOR
Intervention: Drop-set resistance training
Number of subjects: 31
Study 25687834 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix (ADM) with autologous split‐thickness skin
Number of subjects: 30
Study 25687834 — intervention group
Group type: COMPARATOR
Intervention: Control group (autogenous split‐thickness skin implant)
Number of subjects: 30
Study 23370075 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroretentive gabapentin (G-GR) 1800 mg (600 mg AM/1200 mg PM) for 14 weeks
Number of subjects: 80
Study 20389247 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 69
Study 20389247 — intervention group
Group type: COMPARATOR
Intervention: Controlled Home Training (HT)
Number of subjects: 69
Study 20389247 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Supervised Training (ST)
Number of subjects: 69
Study 20389247 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred Training (PT)
Number of subjects: 69
Study 19105823 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitation process of the complex intervention
Number of subjects: 46
Study 19105823 — intervention group
Group type: EXPERIMENTAL
Intervention: Case discussions between link workers and GPs
Number of subjects: 46
Study 19105823 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitators providing advice and manpower
Number of subjects: 46
Study 19105823 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of IT systems
Number of subjects: 46
Study 19105823 — intervention group
Group type: EXPERIMENTAL
Intervention: Reviewing function of the intervention
Number of subjects: 46
Study 19105823 — intervention group
Group type: EXPERIMENTAL
Intervention: Case discussions and improved liaison at times of crisis
Number of subjects: 46
Study 16880481 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 174
Study 16880481 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 174
Study 16880481 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 174
Study 16880481 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching)
Number of subjects: 174
Study 12670814 — intervention group
Group type: EXPERIMENTAL
Intervention: PDA (personal digital assistant)
Number of subjects: 1
Study 12670814 — intervention group
Group type: COMPARATOR
Intervention: Paper-based method
Number of subjects: 1
Study 10822898 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (80 mg/d)
Number of subjects: 26
Study 8639297 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified or classic radical neck dissection
Number of subjects: 159
Study 8639297 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery and radiation
Number of subjects: 159
Study 1323501 — intervention group
Group type: EXPERIMENTAL
Intervention: Ossein-hydroxyapatite compound (OHC) 6.46 g daily for 6 months
Number of subjects: 20
Study 1323501 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bone protective treatment)
Number of subjects: 20
Study 6507131 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol
Number of subjects: 50
Study 6507131 — intervention group
Group type: COMPARATOR
Intervention: metrizamide
Number of subjects: 50
Study 31168851 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Disease Self-Management Program (CDSMP)
Number of subjects: 1067
Study 30197417 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 470
Study 30197417 — intervention group
Group type: COMPARATOR
Intervention: Everolimus
Number of subjects: 470
Study 26659550 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone 20 mg/day
Number of subjects: 150
Study 26659550 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone 60 mg/day
Number of subjects: 150
Study 26659550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 24458316 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT) patches
Number of subjects: 3094
Study 24458316 — intervention group
Group type: COMPARATOR
Intervention: Self-help booklet or cessation website
Number of subjects: 3094
Study 24458316 — intervention group
Group type: COMPARATOR
Intervention: Marijuana use and binge drinking
Number of subjects: 3094
Study 23073480 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser flap creation
Number of subjects: 2
Study 23073480 — intervention group
Group type: COMPARATOR
Intervention: Mechanical microkeratome flap creation
Number of subjects: 2
Study 20056625 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dietary pattern (DM intervention)
Number of subjects: 1676
Study 17884396 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose rate brachytherapy as a boost after external beam chemoradiotherapy
Number of subjects: 16
Study 17884396 — intervention group
Group type: COMPARATOR
Intervention: Conventional preoperative chemoradiotherapy using a bolus 5-fluorouracil regimen
Number of subjects: 16
Study 15609386 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel and aspirin
Number of subjects: 132
Study 15609386 — intervention group
Group type: COMPARATOR
Intervention: Placebo and aspirin
Number of subjects: 132
Study 12115017 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg vitamin C
Number of subjects: 54
Study 12115017 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg vitamin C
Number of subjects: 54
Study 12115017 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 mg vitamin C
Number of subjects: 54
Study 12115017 — intervention group
Group type: COMPARATOR
Intervention: Control (no vitamin C)
Number of subjects: 54
Study 11789184 — intervention group
Group type: EXPERIMENTAL
Intervention: Puerarin 400 mg per day intravenously dripping
Number of subjects: 30
Study 11789184 — intervention group
Group type: COMPARATOR
Intervention: Mikebao 500 micrograms intramuscularly, once per day
Number of subjects: 30
Study 9092223 — intervention group
Group type: EXPERIMENTAL
Intervention: Endarterectomy (n = 825)
Number of subjects: 1659
Study 9092223 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy (n = 834)
Number of subjects: 1659
Study 1640952 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcervical chorionic-villus sampling
Number of subjects: 3999
Study 1640952 — intervention group
Group type: COMPARATOR
Intervention: Transabdominal chorionic-villus sampling
Number of subjects: 3999
Study 6540129 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (i.v. IgG)
Number of subjects: 0
Study 6540129 — intervention group
Group type: COMPARATOR
Intervention: Oral corticosteroids
Number of subjects: 0
Study 30370686 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal metformin (1000 mg) + distal saline
Number of subjects: 10
Study 30370686 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal metformin (1000 mg) + proximal saline
Number of subjects: 10
Study 30370686 — intervention group
Group type: COMPARATOR
Intervention: Proximal + distal saline (control)
Number of subjects: 10
Study 28524358 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (10-week program)
Number of subjects: 51
Study 28524358 — intervention group
Group type: COMPARATOR
Intervention: Control group (no-treatment assessment-only)
Number of subjects: 51
Study 28524358 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected wait-list yoga group (n = 7)
Number of subjects: 51
Study 27572070 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg Q2W
Number of subjects: 62
Study 27572070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 25015544 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitor monotherapy (darunavir/ritonavir or lopinavir/ritonavir)
Number of subjects: 146
Study 25015544 — intervention group
Group type: COMPARATOR
Intervention: Triple drug therapy (two nucleos(t)ides)
Number of subjects: 146
Study 21573944 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate health literacy levels
Number of subjects: 722
Study 21573944 — intervention group
Group type: COMPARATOR
Intervention: Inadequate/marginal functional health literacy
Number of subjects: 722
Study 20397453 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at 7-9 am
Number of subjects: 90
Study 20397453 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at 3-5 pm
Number of subjects: 90
Study 20397453 — intervention group
Group type: COMPARATOR
Intervention: Drug control group
Number of subjects: 90
Study 18672987 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered toothbrush
Number of subjects: 122
Study 18672987 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 122
Study 18672987 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush with floss
Number of subjects: 122
Study 16351669 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg
Number of subjects: 1215
Study 16351669 — intervention group
Group type: COMPARATOR
Intervention: atorvastatin 10 mg
Number of subjects: 1215
Study 16351669 — intervention group
Group type: COMPARATOR
Intervention: simvastatin 20 mg
Number of subjects: 1215
Study 16351669 — intervention group
Group type: COMPARATOR
Intervention: pravastatin 40 mg
Number of subjects: 1215
Study 14563515 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose chemotherapy with primary prophylaxis using hemopoietic growth factors
Number of subjects: 0
Study 14563515 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative strategies in the use of hemopoietic growth factors
Number of subjects: 0
Study 10473984 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical capsaicin
Number of subjects: 200
Study 10473984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 7769318 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (25 mg of base/kg during 3 days or 10 mg of base/kg in one dose) plus primaquine (10 mg/kg during 28 days or 2.5 mg/kg during 3 days)
Number of subjects: 147
Study 7769318 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine plus placebo
Number of subjects: 147
Study 7769318 — intervention group
Group type: EXPERIMENTAL
Intervention: Halofantrine (24 mg base/kg in 12 h)
Number of subjects: 147
Study 2182613 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphatidylcholine (lecithin) 20 g/day
Number of subjects: 21
Study 2182613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 311979 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg Peptide-PABA
Number of subjects: 2
Study 311979 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g Peptide-PABA
Number of subjects: 2
Study 31599995 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention comprising six domiciliary face-to-face sessions and five telephone calls conducted by healthcare professionals and volunteers
Number of subjects: 114
Study 31599995 — intervention group
Group type: COMPARATOR
Intervention: Control group (no systematized intervention)
Number of subjects: 114
Study 30929895 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P13
Number of subjects: 220
Study 30929895 — intervention group
Group type: COMPARATOR
Intervention: Infliximab
Number of subjects: 220
Study 30929895 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CT-P13 and Infliximab
Number of subjects: 220
Study 28215494 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D system
Number of subjects: 277
Study 28215494 — intervention group
Group type: COMPARATOR
Intervention: 2D system
Number of subjects: 277
Study 27352335 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde autologous priming (RAP) for cardiopulmonary bypass (CPB)
Number of subjects: 0
Study 27352335 — intervention group
Group type: COMPARATOR
Intervention: Crystal liquids priming (control)
Number of subjects: 0
Study 23093468 — intervention group
Group type: EXPERIMENTAL
Intervention: Dangling procedure starting at day 3, with wrapping and dangling performed for 5 minutes three times a day, increasing to 60 minutes by day 5.
Number of subjects: 31